Lisata Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
LSTA Nasdaq 2830 www.lisata.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Lisata Therapeutics, Inc.

Lisata Therapeutics moves forward with legal action following Kuva merger termination - Aug 4th, 2026 6:48 am
Lisata Therapeutics Provides Update Following Termination of Merger Agreement - Aug 4th, 2026 5:00 am
Sector Update: Healthcare Stocks Higher Late Afternoon - Jul 24th, 2026 1:35 pm
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share - Jun 10th, 2026 7:36 am
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc. - Jun 10th, 2026 6:00 am
Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances - Mar 9th, 2026 8:29 am
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. - Mar 6th, 2026 4:15 pm
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide - Jan 27th, 2026 6:00 am
Lisata Therapeutics And 2 Other Penny Stocks Worth Watching - Jan 22nd, 2026 5:04 am
How The Evolving Story For Lisata Therapeutics (LSTA) Is Reshaping Its Valuation Outlook - Jan 22nd, 2026 12:07 am
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer - Jan 21st, 2026 5:00 am
Lisata Therapeutics Inc (LSTA) Q3 2025 Earnings Call Highlights: Strategic Alliances and Cost ... - Nov 6th, 2025 10:00 pm
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Nov 6th, 2025 2:05 pm
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’ - Nov 6th, 2025 6:00 am
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent - Nov 4th, 2025 2:00 pm
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025 - Oct 30th, 2025 6:00 am
Lisata Therapeutics to Present at LD Micro Main Event XIX - Oct 13th, 2025 6:00 am
Lisata Therapeutics Partners with Catalent on ADC Technology - Oct 9th, 2025 9:16 am
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement - Oct 8th, 2025 6:30 am
Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Invest In Growth? - Oct 3rd, 2025 9:52 am